

=> d his

(FILE 'HOME' ENTERED AT 16:34:02 ON 12 DEC 2011)

FILE 'MEDLINE, CAPLUS, SCISEARCH, BIOSIS' ENTERED AT 16:34:14 ON 12 DEC
2011

L2 2739 S HU? (L) (CYTOMEGALOVIRUS OR CMV) (L) ENHANCER
 L3 1965 S MOUSE (L) BETA (L) ACTIN (L) PROMOTER
 L4 169 S L2 (L) L3
 L5 62 DUP REM L4 (107 DUPLICATES REMOVED)
 L6 38 S L5 AND PY<=2004
 L7 38 FOCUS L6 1-
 L8 0 S L7 AND (MOUSE BETA?)
 L9 2 S L7 AND (MOUSE (2W) BETA?)
 L10 9 S MOUSE B-ACTIN PROMOTER
 L11 0 S L10 AND L2
 L12 4 DUP REM L10 (5 DUPLICATES REMOVED)

=> d ti so au ab pi l12 1-4

L12 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2011 ACS on STN
 TI Hybrid mouse .beta.-actin promoter with cytomegalovirus
 enhancer/woodchuck hepatitis virus posttranscriptional regulatory element
 and uses

SO PCT Int. Appl., 48 pp.
 CODEN: PIXXD2

IN Tsunoda, Hiroyuki; Habu, Kiyoshi

AB Hybrid promoters prepared by combining various gene promoters and enhancers, and use in production of desired proteins, omnipotent cells, or transgenic animals, are disclosed. It was found that a hybrid promoter comprising a combination of CMV enhancer with a mammalian β -actin promoter or a combination of the Woodchuck Hepatitis Virus posttranscriptional regulatory element (WPRE) with a mammalian β -actin promoter, is superior in activity to the existing promoters. It was also found that the activity of this β -actin promoter is enhanced by the simultaneous expression of an oncogene product Ras which is a transactivator. In this study the authors have enhanced the efficacy of DNA vaccines by adopting strategies that increase gene expression. The authors generated influenza-hemagglutinin (HA)-encoding DNA vaccines that contain the hybrid CMV enhancer/chicken β -actin (CAG) promoter and/or the mRNA-stabilizing post-transcriptional regulatory element from the woodchuck hepatitis virus (WPRE). DNA vaccines consisting of both CAG and WPRE elements (pCAG-HA-WPRE) induced the highest level of protective immunity, such that immunization with 10-fold lower DNA doses prevented death in 100% of the mice upon lethal viral challenge, whereas all mice immunized with the conventional pCMV-HA vaccine succumbed to influenza infection.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
PI WO 2005054467	A1	20050616	WO 2004-JP18006	20041203
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				

STN Search HistoryPrint selected from Online session

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,			
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,			
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,			
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML,			
MR, NE, SN, TD, TG			
AU 2004295590 A1 20050616 AU 2004-295590			20041203
AU 2004295590 B2 20100429			
CA 2548185 A1 20050616 CA 2004-2548185			20041203
EP 1707629 A1 20061004 EP 2004-819918			20041203
EP 1707629 B1 20110608			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			
IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS			
CN 1914320 A 20070214 CN 2004-80041348			20041203
SG 164436 A1 20100929 SG 2010-5748			20041203
EP 2270152 A1 20110105 EP 2010-10437			20041203
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,			
IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA,			
HR, LV, MK, YU			
AT 512232 T 20110615 AT 2004-819918			20041203
KR 2006123413 A 20061201 KR 2006-7013218			20060630
IN 2006DN03783 A 20070713 IN 2006-DN3783			20060630
IN 235423 A1 20090731			
US 20080250514 A1 20081009 US 2007-581183			20070518
IN 2009DN02296 A 20090612 IN 2009-DN2296			20090408